Queen’s University has a highly integrated health research program which operates through the jointly coordinated offices of the Vice-Dean, Research in the Faculty of Health Sciences and Vice President, Health Sciences Research at the Kingston General Hospital. Together our institutions are committed to fostering an environment of transdisciplinary research in a number of biomedical areas and studies of population health and health services research.
Our department has a well-established research program. We are an active site in a number of industry led gynecology trials, investigator led obstetrical studies, and oncology trials through the Clinical Trials Group. We are also actively recruiting for 2 local investigator led clinical trials and several of our staff and residents are leading projects using Ontario-wide data sets available through ICES. Explore below for more information about our research projects!
Departmental Research Program Assistant:
Heather Ramshaw, BSc
Departmental Research Facilitator:
Jessica Pudwell, MPH, MSc
613-549-6666, ext 3937
Departmental Research Nurse:
Christie Hoang, RPN
613-549-6666, ext 2740
Departmental Research Assistant:
Kira King, MLT, BSc
613-549-6666, ext 3937
The sheMATTERS Trial – Dr. Smith
A randomized open-label trial evaluating a nurse-led breastfeeding self-efficacy intervention (BSEI). Following childbirth, breastfeeding mothers who have been diagnosed with a hypertensive disorder of pregnancy will be recruited in to the study. Women will be randomly allocated to the BSEI group or a standard postpartum care group. The trial will evaluate rates of breastfeeding, blood pressure, weight retention, postpartum depression and anxiety, and participant satisfaction at 3, 6 and 12 months postpartum. (NCT04580927)
GRACE (InvestiGational RSV MAternal VaCcinE) - Dr. Smith
A Phase III, randomized, double-blind, placebo-controlled multi-country study to demonstrate efficacy of a single dose of unadjuvanted RSV Maternal vaccine, administered IM to pregnant women 18 to 49 years of age, for prevention of RSV associated LRTI in their infants up to 12 months of age.
Respiratory Syncytial Virus or RSV is a cold-like virus (germ). It infects the airways and lungs. A person with a mild RSV illness may have a cold or a sore throat. A person with severe illness may have problems breathing. By the age of 2 years almost all children have had an RSV illness. Very young babies are more likely to get a severe RSV illness than older children. RSV illness is one of the most common reasons why young babies are admitted to the hospital. In severe cases, babies may die from RSV illness. GSK is testing a new vaccine for pregnant women to protect their babies against RSV. (NCT04605159 & NCT04980391).
Pregnant & LActating Individuals & Newborns COVID-19 Vaccination (PLAN-V) Study - Dr. Gaudet
Information related to COVID-19 vaccines is rapidly evolving. A lack of data on COVID-19 vaccines in pregnant women/individuals makes it challenging for Canadian families to make informed decisions about COVID-19 vaccination. We are conducting a research study at participating hospitals located across Ontario to measure the short and long-term effects of COVID-19 vaccination in pregnancy.
The purpose of this study is to find out what effects COVID-19 vaccines have on the immune systems of pregnant women/individuals and their babies after they are born. We will measure immune responses in vaccinated participants and their babies, and document vaccine-related reactions and health outcomes that may occur after vaccination. (More Information)
Immune Mechanisms in Women with and without Endometriosis - Drs. Tayade, Bougie, Nee and Waddington
Recruiting women with endometriosis at the time of surgery. Sample collection includes a blood sample, endometrial biopsy and peritoneal fluid. Recruiting healthy control women at the time of IUD insertion/removal (in the OR) or at the time of tubal ligation.
Low-Dose Aspirin in the Postpartum Period and Endothelial Function in Patients with Severe Preeclampsia: A Randomized Control Trial - Dr. Smith
Pregnancy provides a window of opportunity for heart disease screening. Pregnancy is a “stress-test” for your heart. Development of preeclampsia can reveal increased risk for heart disease, including high blood pressure, heart attack and stroke. This is especially the case for women who develop severe preeclampsia. It is thought that severe preeclampsia may damage your blood vessels.
The purpose of this study is to determine if low-dose aspirin can lower heart disease risk in women who have had preeclampsia. Some women take low dose aspirin during pregnancy to help prevent preeclampsia. It is also taken by some people to help prevent blood clots or heart disease. Low-dose aspirin is safe to take when pregnant and while breastfeeding. (NCT04243278)
Prognostic Value of Urinary Renal and Vascular Biomarkers in Hypertensive Pregnant Women - Dr. Smith
Preeclampsia usually manifests as an increase of blood pressure and the discovery of proteins in the urine, called proteinuria. Proteinuria is a key feature to diagnose preeclampsia. However, actual methods to mesure proteinuria are not precise enough. We are always seeking greater diagnostic technology to improve the detection of preeclampsia.
This project aims to develop a new approach by combining the measurement of different proteins found in the urine and in the blood to inform us about the health of the mother's kidneys and the placenta during pregnancy. Since the measurement of these proteins is abnormal in women with preeclampsia, we believe that these proteins have the potential for early detection of preeclampsia. The results obtained may lead to better management of pregnant women evaluated for high blood pressure in pregnancy.
For more information about any of these studies please contact us!
firstname.lastname@example.org or 613-549-6666 x3937
Single Dose of Antenatal Corticosteroids (SNACS) Randomized Controlled Trial for Pregnancies at Risk of Preterm Delivery: To Keep Babies and Children Safe
We are interested in understanding whether betamethasone given as a single dose is not any worse (i.e. similar, or not inferior) than the treatment usually given at the usual double doses. The SNACS trial is a large international study including many centers across Canada and Australia. We plan on having approximately 3254 pregnant participants to take part in this study. (NCT04494529)
Cannabis Use in Pregnancy and Downstream effects on maternal and infant health (CUPiD): A pilot prospective cohort study
The primary objective of this study is to assess feasibility for establishing a new prospective cohort of individuals from whom cannabis use and perinatal data can be obtained, and bio-specimens collected. This study will be a multi-centre prospective pilot at The Ottawa Hospital (TOH) and Kingston Health Sciences Centre.
MODE Trial - Dr Gaudet
A pilot trial investigating planned caesarian section versus induction of labour in women with a BMI ≥ 40 kg/m2. ( NCT03985618)
MIREC ENDO – Dr. Velez
Maternal-Infant Research on Environmental Chemicals: Pubertal Timing, Endocrine and Metabolic Function. Pre-pubertal follow up of our previously recruited MIREC cohort is underway. www.mirec-canada.ca/en/
FACT 4 Child – Dr. Smith
Follow up of children in the Folic Acid Clinical Trial (FACT) study. Follow up of our previously recruited FACT cohort is underway. NCT03269110